BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
Female
Humans
Claudin-4
Immunohistochemistry
Mesothelioma, Malignant
Mesothelioma
/ diagnosis
Peritoneal Neoplasms
/ diagnosis
Cystadenocarcinoma, Serous
/ diagnosis
Ovarian Neoplasms
/ diagnosis
Ubiquitin Thiolesterase
/ metabolism
Biomarkers, Tumor
/ metabolism
Diagnosis, Differential
Lung Neoplasms
/ diagnosis
Tumor Suppressor Proteins
Journal
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
ISSN: 1538-7151
Titre abrégé: Int J Gynecol Pathol
Pays: United States
ID NLM: 8214845
Informations de publication
Date de publication:
01 Mar 2023
01 Mar 2023
Historique:
pubmed:
6
5
2022
medline:
11
2
2023
entrez:
5
5
2022
Statut:
ppublish
Résumé
Peritoneal mesothelioma (PM) and serous neoplasms can be difficult to differentiate, particularly in small biopsies. BRCA1-associated protein 1 (BAP1) is expressed in benign tissues, but over 50% of PMs demonstrate complete loss of nuclear expression. Claudin-4, a tight junction protein, is expressed in most epithelial tumors but not in mesotheliomas. Methylthioadenosine phosphorylase (MTAP) is frequently co-deleted with cyclin-dependent kinase inhibitor 2a in mesotheliomas. These markers have proven useful in separating mesothelioma from its mimics, particularly when tumors are pleural based. In the peritoneum, BAP1 loss has been rarely reported in high-grade serous carcinomas, but overall, these markers have been minimally evaluated in ovarian serous borderline tumors and low-grade serous carcinomas. Thus, we assessed the utility of BAP1, claudin-4, and MTAP in the differential diagnosis of PM and low-grade serous neoplasms. Eighteen PM (16 epithelioid, 1 biphasic, and 1 sarcomatous), 24 low-grade serous carcinomas, and 25 serous borderline tumors were stained for BAP1, claudin-4, and MTAP. Loss of BAP1 nuclear expression was observed in 12 (67%) PM (11 epithelioid, 1 biphasic) but was retained in all serous tumors. Claudin-4 was positive in all serous tumors and negative in all PM. Complete loss of cytoplasmic MTAP was noted in 3 (17%) PMs and 1 (4%) serous borderline tumor, while all low-grade serous carcinomas showed retained expression. BAP1 loss reliably distinguishes PM from serous tumors, although it lacks sensitivity. Claudin-4 is a reliable marker to exclude PM. MTAP loss may occur in both PM and serous tumors, and thus is not useful in distinguishing these entities.
Identifiants
pubmed: 35512220
doi: 10.1097/PGP.0000000000000877
pii: 00004347-202303000-00008
doi:
Substances chimiques
5'-methylthioadenosine phosphorylase
EC 2.4.2.28
Claudin-4
0
Ubiquitin Thiolesterase
EC 3.4.19.12
Biomarkers, Tumor
0
BAP1 protein, human
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
159-166Informations de copyright
Copyright © 2022 by the International Society of Gynecological Pathologists.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Foyle A, Al-Jabi M, McCaughey WT. Papillary peritoneal tumors in women. Am J Surg Pathol 1981;5:241–9.
Bollinger DJ, Wick MR, Dehner LP, et al. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma. A histochemical and immunohistochemical comparison. Am J Surg Pathol 1989;13:659–70.
Sheffield BS, Hwang HC, Lee AF, et al. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol 2015;39:977–82.
Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol 2015;28:1043–57.
Facchetti F, Lonardi S, Gentili F, et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 2007;451:669–80.
Hida T, Hamasaki M, Matsumoto S, et al. Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer 2017;104:98–105.
Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING ®nger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097–112.
Davidson B, Tötsch M, Wohlschlaeger J, et al. The diagnostic role of BAP1 in serous effusions. Hum Pathol 2018;79:122–6.
Illei PB, Rusch VW, Zakowski MF, et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003;9:2108–13.
McGregor S, Romero I, Lastra R. BAP1 preserved in BRCA-mutated serous carcinoma. Am J Clin Pathol 2016;146:S1–S26.
Andrici J, Jung J, Sheen A, et al. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol 2016;51:9–15.
Joseph NM, Chen Y, Nasr A, et al. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DD3. Mod Pathol 2017;30:246–54.
Chapel DB, Husain AN, Krausz T, et al. PAX8 expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma. Am J Surg Pathol 2017;41:1675–82.
Choi YL, Kim J, Kwon MJ, et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol 2007;22:1185–95.
Nilforoushan N, Moatamed NA. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression. Ann of Diagn Pathol 2020;48:151582.
Berg KB, Dacic S, Miller C, et al. Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas. Arch Pathol Lab Med 2018;142:1549–53.
Clement PB, Young RH, Scully RE. Malignant mesotheliomas presenting as ovarian masses: a report of nine cases, including two primary ovarian mesotheliomas. Am J Surg Pathol 1996;20:1067–80.
Addis BJ, Fox H. Papillary mesothelioma of ovary. Histopathology 1983;7:287–98.
Wick MR, Mills SE, Dehner LP, et al. Serous papillary carcinomas arising from the peritoneum and ovaries: a clinicopathologic and immunohistochemical comparison. Ing J Gynecol Pathol 1989;8:179–88.
Goldblum J, Hart WR. Localized and diffuse mesotheliomas of the genital tract and peritoneum in women: a clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors. Am J Surg Pathol 1995;19:1124–37.
Bell DA, Scully RE. Serous borderline tumors of the peritoneum. Am J Surg Pathol 1990;14:230–9.
Beebe-Dimmer JL, Fryzek JP, Yee CL, et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol 2016;8:743–50.
Liu S, Staats P, Lee M, et al. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology 2014;46:604–9.
Raju U, Fine G, Greenawald KA, et al. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases. Hum Pathol 1989;20:426–36.
Eichhorn JH, Bell DA, Young RH, et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 1999;23:397–409.
Ahn G, Folkins AK, McKenney JK, et al. Low-grade serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion. Am J Surg Pathol 2016;40:1165–76.
Gershenson DM, Sun CC, Iyer RB, et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2012;125:661–6.
Grisham RN, Iyer G, Sala E, et al. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Int J Gynecol Cancer 2014;24:1010–4.
Gershenson DM, Gourley C, Paul J. MEK inhibitors for the treatment of low-grade serous ovarian cancer: expanding therapeutic options for a rare ovarian cancer subtype. J Clin Oncol 2020;38:3731–4.
Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol 1988;72:775–81.
Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006;19:34–48.
Wieczorek TJ, Krane JF. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer 2000;90:312–9.
Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105–10.
Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA 3—a multispecific but potentially useful marker in surgical pathology—a systematic analysis of 2500 epithelial and non-epithelial tumors. Am J Surg Pathol 2014;38:13–22.
Prabhakaran S, Hocking A, Kim C, et al. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas. Hum Pathol 2020;105:1–8.
Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and ber-ep4: a useful combination of immunohistochemical markers for differentiationg epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007;31:1139–48.
Yoshimura M, Kinoshita Y, Hamasaki M, et al. Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumors. Histopathology 2017;71:1011–4.
Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 2005;123:724–37.
Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2012;43:1022–5.
Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2015;43:668–72.
Nasu M, Emi M, Pastorino S, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 2015;10:565–76.
Tandon RT, Jiminez-Cortez Y, Taub R, et al. Immunohistochemistry in peritoneal mesothelioma: a single-center experience of 224 cases. Arch Pathol Lab Med 2018;142:236–42.
Hwang HC, Pyott S, Rodriguez S, et al. BAP1 immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas. Am J Surg Pathol 2016;40:714–8.
Andrici J, Parkhill TR, Jung J, et al. Loss of expression of BAP1 is very rare in non-small cell lung carcinoma. Pathology 2016;48:336–40.
Schaefer IM, Agaimy A, Fletcher CDM, et al. Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas. Mod Pathol 2017;30:539–48.
Ohta Y, Sasaki Y, Saito M, et al. Claudin-4 as a marker for distinguishing malignant mesothelioma from lung carcinoma and serous adenocarcinoma. Int J Surg Pathol 2013;21:493–501.
Ordonez NG. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol 2013;26:553–62.
Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547–51.
Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008;21:742–7.
Zimling ZG, Jorgensen A, Santoni-Rugiu E. The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas. Histopathology 2012;60:E96–105.
Brich S, Bozzi F, Perrone F, et al. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. Mod Pathol 2020;33:217–27.
Kuo K, Guan B, Feng Y, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009;69:4036–42.
Hunter SM, Anglesio MS, Ryland GL, et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 2015;6:37663–77.
Hung YP, Dong F, Torre M, et al. Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod Pathol 2020;33:2269–79.